Clinical Trial Update: A Randomized, Double-Blind, Placebo Controlled, Two-Period Cross-Over, Proof of Activity Study to Evaluate the Effects of TAK-041 on Motivational Anhedonia as Add-On to Antipsychotics in Participants With Stable Schizophrenia [Phase 2]

View source ↗

Summary

Phase 2 randomized, double-blind, placebo-controlled cross-over study evaluating TAK-041 as add-on to antipsychotics for motivational anhedonia in stable schizo…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizophrenia

Drugs mentioned

• TAK-041 (TAK-041)

Snippet

Sponsor: Neurocrine Biosciences | Conditions: Stable Schizophrenia | Phase 2 | Status: COMPLETED | Results posted: 2021-02-09